Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

TOPOTECAN Drug Profile

« Back to Dashboard

Which patents cover Topotecan, and what generic alternatives are available?

Topotecan is a drug marketed by Sandoz Inc, Sun Pharm Inds Ltd, Actavis Totowa, Mylan Labs Ltd, Accord Hlthcare, Teva Pharms Usa, Ingenus Pharms Llc, Chem Werth Inc, Fresenius Kabi Oncol, Hospira Inc, Sagent Pharms, Fresenius Kabi Usa, Dr Reddys Labs Ltd, and Cipla Ltd. and is included in fourteen NDAs.

The generic ingredient in TOPOTECAN is topotecan hydrochloride. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

Summary for Tradename: TOPOTECAN

Patents:0
Applicants:14
NDAs:14
Suppliers / Packagers: see list1
Bulk Api Vendors: see list40
Clinical Trials: see list117
Patent Applications: see list19,031
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TOPOTECAN at DailyMed

Pharmacology for Tradename: TOPOTECAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc
TOPOTECAN
topotecan hydrochloride
SOLUTION;INTRAVENOUS200199-001Feb 25, 2011DISCNYesNo► Subscribe► Subscribe
Accord Hlthcare
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION202351-001Jun 26, 2013APRXNoNo► Subscribe► Subscribe
Sun Pharm Inds Ltd
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION202203-001Aug 29, 2013APRXNoNo► Subscribe► Subscribe
Hospira Inc
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
SOLUTION;INTRAVENOUS200582-001Feb 2, 2011APRXYesYes► Subscribe► Subscribe
Teva Pharms Usa
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
SOLUTION;INTRAVENOUS022453-001Dec 20, 2012APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Find generic sources and suppliers
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot